a small-molecule inhibitor
ChemicalBook > CAS DataBase List > Imatinib mesylate

Imatinib mesylate

a small-molecule inhibitor
Product Name
Imatinib mesylate
CAS No.
220127-57-1
Chemical Name
Imatinib mesylate
Synonyms
GLEEVEC;GLIVEC;Imatinib (Glivec);STI-571;Gleevac;CGP 57148;CGP54148B;Genfatinib;CGP-57148B;tinib Mesylate
CBNumber
CB7173646
Molecular Formula
C30H35N7O4S
Formula Weight
589.71
MOL File
220127-57-1.mol
More
Less

Imatinib mesylate Property

Melting point:
214-224°C
storage temp. 
2-8°C
solubility 
H2O: soluble10mg/mL, clear
form 
White solid
color 
white to beige
Stability:
Stable for 1 year from date of purchase as supplied. Solutions in DMSO or water may be stored at -20°C for up to 3 months.
InChI
InChI=1S/C29H31N7O.CH4O3S/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36;1-5(2,3)4/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34);1H3,(H,2,3,4)
InChIKey
YLMAHDNUQAMNNX-UHFFFAOYSA-N
SMILES
C(NC1=CC=C(C)C(NC2=NC=CC(C3=CC=CN=C3)=N2)=C1)(=O)C1=CC=C(CN2CCN(C)CC2)C=C1.CS(O)(=O)=O
CAS DataBase Reference
220127-57-1(CAS DataBase Reference)
More
Less

Safety

Hazard Codes 
Xn
Risk Statements 
22
WGK Germany 
3
RTECS 
CV5520550
HS Code 
29350090
Hazardous Substances Data
220127-57-1(Hazardous Substances Data)
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Precautionary statements

P201Obtain special instructions before use.

P202Do not handle until all safety precautions have been read and understood.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P308+P313IF exposed or concerned: Get medical advice/attention.

P405Store locked up.

P501Dispose of contents/container to..…

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
SML1027
Product name
Imatinib mesylate
Purity
≥98% (HPLC)
Packaging
10mg
Price
$43.5
Updated
2024/03/01
Sigma-Aldrich
Product number
SML1027
Product name
Imatinib mesylate
Purity
≥98% (HPLC)
Packaging
100mg
Price
$149
Updated
2024/03/01
Sigma-Aldrich
Product number
5.04595
Product name
Bcr-abl Inhibitor IV, Imatinib - CAS 220127-57-1 - Calbiochem
Packaging
50mg
Price
$155
Updated
2024/03/01
TCI Chemical
Product number
I0936
Product name
Imatinib Mesylate
Purity
>98.0%(HPLC)
Packaging
100mg
Price
$54
Updated
2024/03/01
TCI Chemical
Product number
I0936
Product name
Imatinib Mesylate
Purity
>98.0%(HPLC)
Packaging
1g
Price
$314
Updated
2024/03/01
More
Less

Imatinib mesylate Chemical Properties,Usage,Production

a small-molecule inhibitor

Imatinib mesylate (also called Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukemia.
As an inhibitor of PDGFR, imatinib mesylate appears to have utility in the treatment of a variety of dermatological diseases. Imatinib has been reported to be an effective treatment for FIP1L1-PDGFRalpha+ mast cell disease, hypereosinophilic syndrome, and dermatofibrosarcoma protuberans.

Description

In May 2001, the FDA approved imatinib as a new cancer drug after a record review time of just 2.5 months. Imatinib was launched as Gleevec in the US for chronic myelogenous leukemia (CML) in blast crisis, accelerated phase or chronic phase after interferon-alpha failure. This compound can be prepared by a four step sequence from a condensation of the 1-(3-pyridyl)ethanone with dimethyl formamide dimethylacetal, followed by successive cyclization with the methyl-nitrophenyl guanidine, hydrogenolysis and condensation with the benzoyl chloride of the methylpiperazine. Imatinib is the first of a new class of anticancer drugs that are specifically designed to target the molecular pathways involved (oncogenic event) in the development of disease. The Brc-Abl oncoprotein is a constitutively active tyrosine kinase that causes CML. Imatinib is a competitive inhibitor of this tyrosine kinase as well as Abl, Kit and the PDGFR kinases It binds to the ATP-binding site of the target kinase and prevents the transfer of phosphate from ATP to the tyrosine residues of various substrates and consequently blocks the proliferation of the leukemic cells. Phase II studies demonstrated that in chronic phase CML, over 90% of the patients had their leukocyte counts return to normal and 56% had a major cytogenic response. No phase III data is currently available. It is clear from the evidence available that imatinib has advantages over IFN-alpha, such as reduced toxicity, more rapid hematological response, higher rate of cytogenic response and oral administration. The drug is well tolerated, producing few side effects, classified as grade 1 nausea, muscle cramps, diarrhea, edema and vomiting. Imatinib is metabolized primarily by the CYP3A4 enzyme system and drugs capable of modulating this system would be expected to modify the patient's exposure. Novartis expects to launch imatinib for the treatment of gastrointestinal stromal tumors in 2002.

Chemical Properties

Off-White Solid

Originator

Novartis (Switzerland)

Uses

A tyrosine kinase inhibitor. Highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL)

Uses

Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. Imatinib also known as Gleevec, Glivec, CGP-57148B, STI-571 & Imatinib

Uses

Imatinib Mesylate (STI571) is an orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively.

Uses

echinocandin antifungal, active against infections with Aspergillus and Candida, inhibits cell wall synthesis

Definition

ChEBI: A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.

brand name

Gleevec, Glivec

General Description

Imatinib is available in 100- and 400-mg capsules for oraladministration and is indicated for the treatment of CML,gastrointestinal stromal tumors (GIST) that express Kit andacute lymphoplastic leukemia that is positive for thePhiladelphia chromosome.
Bioavailability of the agent is nearly 100% by the oralroute. The agent is highly protein bound and metabolized tothe N-desmethyl derivative by CYP3A4-mediated removalof the piperazinyl methyl group. The resulting metabolite issimilar to the parent in activity. Elimination occurs primarilyin the feces, and the terminal half-life is 18 hours forthe parent and 40 hours of the N-desmethyl metabolite.Resistant forms of the TK are known, which have alteredamino acids that prevent binding. In addition, there may beincreased levels of the kinase itself. The drug is also a substratefor Pgp and an additional efflux transporter known asbreast cancer resistance protein (BCRP), both of which removethe drug from the cell. These transporters are also inhibitedby the agent as well. Severe side effects include ascites,neutropenia, thrombocytopenia, skin rash, andpulmonary edema. Less serious side effects include nausea/vomiting, heartburn, and headache but overall, the agentis better tolerated than most other medications used in treatingthe disease.

Biochem/physiol Actions

Imatinib mesylate is a tyrosine kinase inhibitor with antineoplastic activity. Imatinib is a potent inhibitor of the Bcr-Abl kinase encoded by the bcr-abl oncogene as well as receptor tyrosine kinases encoded by c-kit and platelet-derived growth factor receptor (PDGFR) oncogenes. Imatinib mesylate inhibition of Bcr-Abl tyrosine kinase created by the Philadelphia chromosome abnormality found in CML decreases proliferation and enhances apoptosis in leukemias CML and ALL. Inhibition of c-kit tyrosine activity inhibits mast-cell and cellular proliferation in those diseases overexpressing c-kit such as gastrointestinal stromal tumor (GIST).

storage

+4°C

References

1) Buchdunger, et al.(1996) Inhibition of the Abl Protein-Tyrosine Kinase in Vitro and in Vivo by a 2-Phenylpyrimidine Derivative; Cancer Res. 56 100 2) Heinrich et al (2000) Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96 925 3) Morioka et al. (2016) Effect of Collagen Type 1 or Human Fibronectin on Imatinib Cytotoxicity in Oral Squamous Cell Carcinoma; Pharmacology and Pharmacy, 7 255 [Focus Biomolecules Citation] 4) Hazekawa et al. (2017) Assessment of cytotoxicity of imatinib for oral squamous cell carcinoma by a real-time cell analysis system; E. J. Bio., 13 56 [ Focus Biomolecules Citation]

Imatinib mesylate Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Imatinib mesylate Suppliers

Americas 1 Argentina 1 Australia 1 Brazil 2 Canada 8 China 525 China Hong Kong 1 Cyprus 1 Czech Republic 2 Europe 4 France 2 Germany 6 Greece 1 India 114 Israel 1 Italy 1 Japan 1 Jordan 1 Latvia 1 Mexico 1 Poland 2 South Korea 5 Spain 1 Switzerland 2 The Netherlands 1 Turkey 1 United Arab Emirates 1 United Kingdom 14 United States 66 Global 768
TCI Chemicals (India) Pvt. Ltd.
Tel
--
Fax
--
Email
sales-in@tcichemicals.com
Country
India
ProdList
6768
Advantage
58
Triveni chemicals
Tel
--
Fax
--
Email
sales@trivenichemical.com
Country
India
ProdList
6088
Advantage
58
Trignokem International.
Tel
--
Fax
--
Email
ignokem@gmail.com
Country
India
ProdList
233
Advantage
58
Orbit Lifescience Pvt., Ltd.
Tel
--
Fax
--
Email
orbit@orbitlifescience.com
Country
India
ProdList
206
Advantage
58
Oceanic Pharmachem Pvt., Ltd. (OPPL)
Tel
--
Fax
--
Email
info@oceanicpharmachem.com
Country
India
ProdList
946
Advantage
58
Heilen Biopharm Pvt. Ltd.
Tel
--
Fax
--
Email
info@heilenbiopharm.com
Country
India
ProdList
39
Advantage
58
Almon Industries
Tel
--
Fax
--
Email
ankit@almonindustries.com
Country
India
ProdList
10
Advantage
58
Arunodaya Pharma Pvt., Ltd.
Tel
--
Fax
--
Email
arunodayapharma@gmail.com
Country
India
ProdList
62
Advantage
58
Khandelwal Laboratories Pvt., Ltd.
Tel
--
Fax
--
Email
mktg@khandelwallab.com
Country
India
ProdList
25
Advantage
58
HRV Global Life Sciences Private Limited
Tel
--
Fax
--
Email
info@hrvglobal.com
Country
India
ProdList
190
Advantage
58
Kkyemistry (india) Pvt., Ltd.
Tel
--
Fax
--
Email
marketing@kyemistryindia.com
Country
India
ProdList
163
Advantage
58
Aartia KEM Science
Tel
--
Fax
--
Email
sales@aartiakem.com
Country
India
ProdList
32
Advantage
58
SHILPA MEDICARE LTD
Tel
--
Fax
--
Email
info@vbshilpa.com
Country
India
ProdList
52
Advantage
58
Pharma Chemicals
Tel
--
Fax
--
Country
India
ProdList
130
Advantage
58
Process Speciality Chemicals
Tel
--
Fax
--
Country
India
ProdList
31
Advantage
58
Aligns International
Tel
--
Fax
--
Email
info@aligns.in
Country
India
ProdList
137
Advantage
58
S. Zhaveri Pharmakem Pvt. Ltd
Tel
--
Fax
--
Email
info@szhaveri.net
Country
India
ProdList
112
Advantage
58
DR. Madhukar Pharmaceuticals (P) Limited
Tel
--
Fax
--
Email
prasad@madhukarpharma.com
Country
India
ProdList
13
Advantage
58
Bulat Pharmaceutical Pvt. Ltd.
Tel
--
Fax
--
Email
info@bulatpharmaceutical.com
Country
India
ProdList
35
Advantage
58
Dharmanandan Export Pvt., Ltd.
Tel
--
Fax
--
Email
info@dnexport.com
Country
India
ProdList
161
Advantage
58
Cipla Ltd.
Tel
--
Fax
--
Email
exports@cipla.com
Country
India
ProdList
72
Advantage
58
NATCO PHARMA LIMITED
Tel
--
Fax
--
Email
info@natcopharma.sg.
Country
India
ProdList
24
Advantage
58
MAC CHEM PRODUCTS (INDIA) PVT. LTD.
Tel
--
Fax
--
Email
info@macchemgroup.com
Country
India
ProdList
39
Advantage
58
Vyshno Bio Sciences
Tel
--
Fax
--
Email
info@vyshnobio.com
Country
India
ProdList
239
Advantage
58
Albios Lifesciences Private Limited
Tel
--
Fax
--
Email
info@albioslifesciences.com
Country
India
ProdList
51
Advantage
58
Gia Pharma
Tel
--
Fax
--
Country
India
ProdList
29
Advantage
58
Raising Sun Pharma
Tel
--
Fax
--
Email
info@raisingsunpharma.com
Country
India
ProdList
66
Advantage
58
Athos Chemicals
Tel
--
Fax
--
Email
export@athoschemicals.com
Country
India
ProdList
315
Advantage
58
Eastern Chemicals (Mumbai) Pvt., Ltd.
Tel
--
Fax
--
Email
info@ecmpl.com
Country
India
ProdList
104
Advantage
58
Nivon Specialties (India)
Tel
--
Fax
--
Email
info@nivonindia.com
Country
India
ProdList
154
Advantage
58
Ralington Pharma
Tel
--
Fax
--
Email
info@ralingtonpharma.com
Country
India
ProdList
312
Advantage
58
Opulent Pharma
Tel
--
Fax
--
Country
India
ProdList
810
Advantage
58
Angels Pharma India Private Limited.
Tel
--
Fax
--
Email
info@angelspharma.com
Country
India
ProdList
6
Advantage
58
Basil Pharmaceuticals
Tel
--
Fax
--
Email
backoffice@basilpharmaceutical.com
Country
India
ProdList
53
Advantage
58
Rensun Pharmaceuticals Pvt Ltd.
Tel
--
Fax
--
Email
rensun@mtnl.net.in
Country
India
ProdList
152
Advantage
58
Reva Pharmachem (P) Ltd.
Tel
--
Fax
--
Email
info@revapharma.com
Country
India
ProdList
31
Advantage
58
Pharma Affiliates
Tel
--
Fax
--
Email
@pharmaffiliates.com
Country
India
ProdList
6754
Advantage
58
Ayon PharmaChem
Tel
--
Fax
--
Email
bhargav@ayonpharmachem.com
Country
India
ProdList
303
Advantage
58
Indo Pharma
Tel
--
Fax
--
Email
indopharm@gmail.com
Country
India
ProdList
99
Advantage
58
Manus Aktteva Biopharma LLP
Tel
--
Fax
--
Country
India
ProdList
655
Advantage
58
VAV Life Sciences Pvt. Ltd.
Tel
--
Fax
--
Email
enquiry@vav.in
Country
India
ProdList
12
Advantage
58
Gland Chemicals
Tel
--
Fax
--
Email
malleswararao@glandpharma.com
Country
India
ProdList
13
Advantage
58
FRESENIUS KABI ONCOLOGY LIMITED
Tel
--
Fax
--
Email
contactus.india@fresenius-kabi.com
Country
India
ProdList
24
Advantage
58
Anantco Enterprises Pvt., Ltd.
Tel
--
Fax
--
Email
anantco@anantco.com
Country
India
ProdList
71
Advantage
58
ZEON Drugs Pvt. Ltd.(ZEON Health Industries)
Tel
--
Fax
--
Email
info@zeonpharma.com
Country
India
ProdList
48
Advantage
58
Goalsy Laboratories
Tel
--
Fax
--
Email
info@goalsylaboratories.com
Country
India
ProdList
42
Advantage
58
Exim Corporation
Tel
--
Fax
--
Email
info@eximcorp.com
Country
India
ProdList
179
Advantage
58
Ind-Swift Laboratories Ltd.
Tel
--
Fax
--
Email
info@indswiftlabs.com
Country
India
ProdList
28
Advantage
58
Vannsh Life Sciences Private Limited
Tel
--
Fax
--
Email
venkat@vannshlifesciences.com
Country
India
ProdList
9
Advantage
58
Kevy's Labs
Tel
--
Fax
--
Email
kevyslabs@rocketmail.com
Country
India
ProdList
29
Advantage
58
More
Less

View Lastest Price from Imatinib mesylate manufacturers

Sinoway Industrial co., ltd.
Product
Imatinib Mesylate 220127-57-1
Price
US $650.00-350.00/KG
Min. Order
1KG
Purity
High Density
Supply Ability
20 tons
Release date
2023-11-03
WUHAN FORTUNA CHEMICAL CO., LTD
Product
Imatinib mesylate 220127-57-1
Price
US $0.00-0.00/Kg/Drum
Min. Order
1KG
Purity
98%-102% HPLC
Supply Ability
500KGS
Release date
2021-07-05
Nanjing Fred Technology Co., Ltd
Product
Imatinib mesylate 220127-57-1
Price
US $0.00-0.00/kg
Min. Order
1kg
Purity
99.9%(HPLC)
Supply Ability
10 tons
Release date
2023-12-06

220127-57-1, Imatinib mesylateRelated Search:

2-Aminopyridine Methyl acrylate Thiophanate-methyl 3-Aminopyridine Gatifloxacin mesylate Pazufloxacin mesilate Pefloxacin mesylate Methyl acetate Methylparaben Bensulfuron methyl 4-Dimethylaminopyridine Kresoxim-methyl Methyl 1,2,3-Triacetyl-5-deoxy-D-ribose Gemcitabine Gemcitabine hydrochloride 4-Chloromethyl-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide N-DESMETHYL IMATINIB

  • 4-[(4-methyl-1-piperazinyl)methyl]-n-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide monomethanesulfonate
  • STI-571
  • IMATINIB BASE(IMA-3)
  • ImatinibMesylate/Gleevec
  • Imatinib Methanesulfonate, STI-571, CGP-57148B, Glivec,
  • IMATINIB MESYLATE (IMATINIB METHANESULFONATE)
  • alpha-IMATINIB MESYLATE
  • Imatinib mesylate(TINIBS )
  • Imatinib mesylate
  • Imatinib Methanesulphonate Salt
  • N-(4-Methyl-3-((4-(pyridin-3-yl)pyriMidin-2-yl)aMino)phenyl)-4-((4-Methylpiperazin-1-yl)Methyl)benzaMide Methanesulfonate
  • N-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide methanesulfonic acid
  • ST-1571 Mesylate
  • Imatinib mesylate 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide monomethanesulfonate
  • 4-[(4-Methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide mesylate
  • CGP 57148
  • Genfatinib
  • Imatinib mesylate, >=99%
  • 4-(4-methylpiperazinomethyl)benzoyl chloride dihydrochloride
  • 4-(4-Methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)phenyl]benz
  • Bcr-abl Inhibitor IV, Imatinib
  • Imatinib mesylate(alpha Form)
  • Imatinib (STI-571) Mesylate
  • Imatinib Mesylate 220127-57-1
  • IMATINIB MESYLATE (STI571 MESYLATE)
  • Imatinib mesylate - CGP 57148B | STI 571 | Gleevec
  • GLIVEC; CGP-57148B; STI-571
  • 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide
  • Imatinib mesylate / 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate
  • Gleevec (Imatinib)
  • IMatinib Mesylate(STI-571)
  • Gleevec, Glivec, CGP-57148B, STI-571
  • 4-[(4-Methyl-1-piperazinyl)Methyl]-N-[4-Methyl-3-[[4-(3-pyridinyl)-2-pyriMidinyl]aMino]phenyl]benzaMide Methanesulfonate
  • GLIVEC
  • GLEEVEC
  • IMATINIB METHANESULFONATE
  • CGP-57148B
  • 4-[(4-methylpiperazin-1-yl)methyl]-n-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate
  • Gleevac
  • Gleevec (IMatinib Mesylate)
  • CGP54148B
  • CGP54148B; STI571; GLEEVEC;GLIVEC
  • 4-(4-Methylpiperazin-1-ylMethyl)-N-[4-Methyl-3-(4-pyridin-3-yl-pyriMidin-2-ylaMino)phenyl]benzaMide Methanesulfonic acid salt
  • Imantinib mesylate
  • N-(4-Methyl-3-((4-(pyridin-3-yl)pyriMidin-2-yl)aMino)phenyl)-4-(4-Methylpiperazin-1-yl)benzaMide Methanesulfonate
  • tinib Mesylate
  • Imatinib mesylate (Gleevec, Glivec, CGP-57148B, STI-571)
  • Imatinib for system suitability
  • Bcr-abl Inhibitor IV, Imatinib - CAS 220127-57-1 - Calbiochem
  • Imatinib (Glivec)
  • Imatinib for system suitability CRS
  • Imatinib mesilate CRS
  • Imatinib mesylate salt
  • ImatinibMesylate&gt
  • Imatinib Mesylate β form
  • Imatinib mesyL
  • Imatinib mesylate(API)
  • Imatinib mesylate USP/EP/BP